The relevance of living supports on antiplatelet adherence and trial participation: the SPS3 trial

被引:1
|
作者
Lewis, Brandy L. [1 ]
Pearce, Lesly A.
Field, Thalia S. [1 ]
White, Carole L. [2 ]
Benavente, Oscar R. [1 ]
机构
[1] Univ British Columbia, Div Neurol, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada
[2] Univ Texas Hlth Sci Ctr San Antonio, Sch Nursing, San Antonio, TX 78229 USA
基金
美国国家卫生研究院;
关键词
stroke; retention; adherence; antiplatelet therapy; clinical trial; living support; QUALITY-OF-LIFE; SECONDARY PREVENTION; PATIENT ADHERENCE; SOCIAL SUPPORT; ACUTE STROKE; ARRANGEMENT; ASPIRIN; MODELS; CARE;
D O I
10.1111/ijs.12267
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background While living with others has been associated with improved functional outcome after acute stroke, it is unclear if this affects adherence to stroke prevention measures. Aims We examined the relationship between living arrangements and adherence to antiplatelet therapy assignment and participation status in an international randomized trial for secondary stroke prevention. Method Antiplatelet therapy adherence, trial retention outcomes, and baseline characteristics for participants enrolled in the Secondary Prevention of Small Subcortical Strokes study were compared between those who lived alone vs. with others (n = 2374). Participant status at end-of-trial was categorized into (1) on assigned antiplatelet, (2) off assigned antiplatelet by participant request, or (3) participant withdrew consent/lost to follow-up. Multivariable multivariate logistic regression was used to identify patient features at entry predictive of participant status at trial end. Results Living arrangement, alone vs. with other(s), was not significantly associated with participant status. Participants enrolled in the United States/Canada (odds ratio 3 center dot 1, confidence intervals 2 center dot 0-5 center dot 0, vs. Latin America), taking more (7+) prescription medications (odds ratio 1 center dot 7, confidence intervals 1 center dot 1-2 center dot 7, vs. 0-2 medications), and scoring lower on the Stroke Specific Quality of Life scale (odds ratio 1 center dot 3, confidence intervals 1 center dot 1-1 center dot 5, per 10 points) were more likely to withdraw or become lost to follow-up in the study vs. completing the study on assigned antiplatelet therapy. Participants enrolled in the United States/Canada (odds ratio 5 center dot 0, confidence intervals 2 center dot 4-10 center dot 0, vs. Latin America) and taking fewer (0-2) medications (odds ratio 1 center dot 9, confidence intervals 1 center dot 2-3 center dot 1 vs. 3-6 medications) were more likely to request discontinuation of assigned antiplatelet medication vs. completing the study. Conclusion Living with others was not independently predictive of protocol adherence in this cohort. Number of medications and Stroke Specific Quality of Life scale score may be more indicative of likelihood of trial participation and acceptance of long-term antiplatelet regimen.
引用
收藏
页码:443 / 448
页数:6
相关论文
共 50 条
  • [1] Lessons from the SPS3 trial
    Turgeon, Ricky D.
    LANCET, 2014, 383 (9916): : 512 - 513
  • [2] Cognitive impairment in lacunar strokes: The SPS3 trial
    Jacova, Claudia
    Pearce, Lesly A.
    Costello, Raymond
    McClure, Leslie A.
    Holliday, Stephen L.
    Hart, Robert G.
    Benavente, Oscar R.
    ANNALS OF NEUROLOGY, 2012, 72 (03) : 351 - 362
  • [3] Intracranial Wall Irregularity and Recurrent Stroke: the SPS3 Trial
    Ohara, Nobuyuki
    Nakajima, Makoto
    Pearce, Lesly A.
    Feldmann, Edward
    Bazan, Carlos
    Hart, Robert G.
    Liebeskind, David S.
    Benavente, Oscar R.
    STROKE, 2015, 46
  • [4] Intracranial Dolichoectasia in Patients with Lacunar Strokes: The SPS3 Trial
    Nakajima, Makoto
    Pierce, Lesley
    Bazan, Carlos
    Hart, Robert G.
    McClure, Leslie
    Benavente, Oscar R.
    STROKE, 2013, 44 (02)
  • [5] Metabolic Syndrome in Patients with Lacunar Stroke: The SPS3 trial
    Zhu, S.
    McClure, L. A.
    Pikula, A.
    Lau, H.
    Kase, C.
    White, C.
    Babikian, V.
    Romero, J. R.
    Nguyen, T.
    Benavente, O.
    CEREBROVASCULAR DISEASES, 2014, 37 : 632 - 632
  • [6] Noninvasive Fractional Flow on MRA and Recurrent Stroke: SPS3 Trial
    Nakajima, Makoto
    Ohara, Nobuyuki
    Pearce, Lesly A.
    Feldmann, Edward
    Bazan, Carlos
    Liebeskind, David S.
    Hart, Robert G.
    Benavente, Oscar R.
    STROKE, 2015, 46
  • [7] The Impact of Blood Pressure Variability on Stroke Recurrence: The SPS3 trial
    Field, T. S.
    Patton, K. L.
    McClure, L. A.
    Sussman, C. R.
    White, C. L.
    Pergola, P. E.
    Cervantes-Arriaga, A.
    Conwit, R. A.
    Hart, R. G.
    Benavente, O. R.
    CEREBROVASCULAR DISEASES, 2013, 35 : 111 - 111
  • [8] Abnormal Left Ventricular Geometry in Lacunar Stroke: the SPS3 Trial
    Chan-Smyth, N.
    Field, T.
    Pearce, L. A.
    Asinger, R. W.
    Hart, R. G.
    Benavente, O. R.
    STROKE, 2014, 45 (12) : E259 - E259
  • [9] Localization Of Lacunar Syndromes Within The Brain: Mri Findings In The Sps3 Trial
    Mirsen, Thomas R.
    Szychowski, Jeff
    Benavente, Oscar
    STROKE, 2011, 42 (03) : E70 - E70
  • [10] Increased Blood Pressure Variability in the SPS3 Trial is Associated With Recurrent Stroke
    de Havenon, Adam
    Tirschwell, David
    Stoddard, Greg
    Majersik, Jennifer
    Rost, Natalia
    STROKE, 2019, 50